Cefuroxime


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Susceptible infections As cefuroxime axetil: 250 or 500 mg 12 hourly for 7-10 days. Uncomplicated UTI 250 mg 12 hourly for 7-10 days. Resp tract infections250 - 500 mg 12 hourly for 7-10 days. Lyme disease 500 mg bid for 20 days. Uncomplicated gonorrhoea 1 g as a single dose. May be given w/ oral probenecid 1 g. IM/IV Susceptible infections 0.75 g 8 hrly, may increase up to 1.5 g 6-8 hrly in more severe infections. Pneumonia 1.5 g bid, followed by an oral dose of 0.5 g bid. Acute exacerbations of chronic bronchitis 750 mg bid, followed by an oral dose 500 mg bid. Prophylaxis of surgical infections 1.5 g IV before the procedure, followed by 750 mg IM 8 hrly for up to 24-48 hr. For total joint replacement: 1.5 g, may be mixed w/ methylmethacrylate cement. IV Meningitis 3 g 8 hrly. IM Gonorrhoea 1.5 g as a single dose divided between 2 inj sites. May be given w/ oral probenecid 1 g.
Administration
Cefuroxime: May be taken with or without food.
Cefuroxime: Should be taken with food.
Contraindications
Hypersensitivity to cefuroxime or to other cephalosporins.
Special Precautions
History of hypersensitivity to penicillin, and GI disease (particularly colitis). Renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor renal, hepatic and haematologic function periodically. Monitor prothrombin time in patients at risk of prolongation. Observe for signs and symptoms of anaphylaxis during 1st dose.
Adverse Reactions
Rash, fever, pruritus, erythema, urticaria, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, serum sickness-like reactions, angioedema; mild to moderate hearing loss (childn); nausea, vomiting, gagging, epigastric burning, GI bleeding and infection, abdominal pain, flatulence, ptyalism, indigestion, mouth ulcers, swollen tongue, anorexia, thirst, dyspepsia, stomach cramps, diarrhoea; decreased Hb and haematocrit, thrombocytosis, lymphocytosis, haemolytic anaemia, increased prothrombin time; transient increase in serum AST (SGOT), ALT (SGPT), alkaline phosphatase, LDH and bilirubin levels; transient increase in BUN and/or serum creatinine concentration, decreased CrCl, bilateral renal cortical necrosis; UTI, kidney pain, urethral pain or bleeding, dysuria, vaginitis, vag candidiasis, vulvovaginal pruritus, vag discharge or irritation; Jarisch-Herxheimer reaction; neck muscle spasm, muscle cramps or stiffness, chest pain or tightness, shortness of breath, tachycardia, chills, lockjaw-type reaction, viral illness, upper resp infection, sinusitis, cough, joint swelling, arthralgia; pain at inj site, thrombophlebitis (IV). Rarely, transient eosinophilia and neutropenia, pancytopenia, leucopenia, thrombocytopenia; headache, somnolence or sleepiness, dizziness, hyperactivity, irritable behaviour, myoclonic jerks, seizures, generalised hyperexcitability; jaundice; acute renal failure, interstitial nephritis.
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.
Drug Interactions
May enhance the nephrotoxic effect of strong-acting diuretics (e.g. furosemide) and aminoglycosides. May enhance the effect of oral anticoagulants. May reduce the efficacy of OCs. Probenecid prolongs the excretion of cefuroxime and elevated peak serum level.
CIMS Class
ATC Classification
S01AA27 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the treatment of eye infections.
J01DC02 - cefuroxime ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefuroxime from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in